Sector ratings Novo Nordisk A/S

Equities

Real-time Estimate Cboe Europe Other stock markets 11:32:30 15/04/2026 BST			5-day change	1st Jan Change
253.42 ^DKK	+2.96%		+5.87%	-21.84%

09:55am	European shares pause as investors assess corporate earnings, Middle East developments	RE
08:48am	SB1 initiates coverage of Novo Nordisk with Buy rating - valuation discount seen as excessive	FW

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
NOVO NORDISK A/S	172B		A
ELI LILLY AND COMPANY	825B		A
JOHNSON & JOHNSON	578B		BBB
ABBVIE INC.	372B		AA
ROCHE HOLDING AG	326B		AA			-		-
ASTRAZENECA PLC	314B		A
MERCK & CO., INC.	296B		A
NOVARTIS AG	294B		AAA
AMGEN INC.	189B		A
GILEAD SCIENCES, INC.	174B		AA
PFIZER INC.	154B		A
BRISTOL-MYERS SQUIBB COMPANY	119B		A
GSK PLC	119B		AA
SANOFI	115B		AA
VERTEX PHARMACEUTICALS INCORPORATED	113B		AA
CHUGAI PHARMACEUTICAL CO., LTD.	88.29B		AA
ALLERGAN PLC	63.66B	-	-	-	-	-	-	-
TAKEDA PHARMACEUTICAL COMPANY LIMITED	55.75B		AA
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	54.61B		AA
BAYER AG	47.08B		AA
Average	223.55B		AA
Weighted average by Cap.			AA